S+ SimulationsPlus

Earnings Call – Q1 - FY25

January 7, 2025



Safe Harbor Statement



Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "expect," and "anticipate" mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully integrate the Pro-ficiency business with our own, as well as expenses we may incur in connection therewith, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Non-GAAP Financial Measures

This press release includes certain financial measures not presented in accordance with generally accepted accounting principles ("GAAP") such as Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Diluted EPS and certain ratios and other metrics derived there from. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP. You should be aware that the presentation of these measures may not be comparable to similarly-titled measures used by other companies. We believe (i) these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends; and (ii) that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are set forth in the appendix to this presentation.

First Quarter Highlights



CURRENT PERIOD

\$18.9M Revenue	+31% Revenue Growth	\$0.01 Diluted EPS	\$0.17 Adj. Diluted EPS	24% Adj. EBITDA Margin
Prior Year Comp \$14.5M	oarison (1Q24) +21%	\$0.10	\$0.18	23%
Revenue	Revenue Growth	Diluted EPS	Adj. Diluted EPS	Adj. EBITDA Margin

Trailing Twelve Months (TTM) 1Q25 Highlights

S#

CURRENT PERIOD

\$74.4M Revenue	+20% Revenue Growth	\$0.40 Diluted EPS	\$0.94 Adj. Diluted EPS	29% Adj. EBITDA Margin
Prior Year Com	parison (1Q24)			
\$62.1M Revenue	+16% Revenue Growth	\$0.52 Diluted EPS	\$1.06 Adj. Diluted EPS	34% Adj. EBITDA Margin

Software Highlights




General	— G	iood renewal rate, upsell	growth of 41% for 1Q25 a and new logo activity n ALI and MC in-line with		
Cheminformatics (CHEM)	Physiologically Based Pharmacokinetics (PBPK)	Clinical Pharmacology & Pharmacometrics (CPP)	Quantitative Systems Pharmacology (QSP)	Adaptive Learning & Insights (ALI)	Medical Communications (MC)
+15%	+4%	+43%	+40%	\$1.7M	\$0.1M
Q1 Revenue Growth	Q1 Revenue Growth	Q1 Revenue Growth	Q1 Revenue Growth	Q1 Revenue	Q1 Revenue
+7%	+4%	+28%	-5%	\$2.8M	\$0.1M
TTM Revenue Growth	TTM Revenue Growth	TTM Revenue Growth	TTM Revenue Growth	TTM Revenue ⁽¹⁾	TTM Revenue ⁽¹⁾

⁽¹⁾ The TTM revenue for the ALI and MC business units only includes revenue since the acquisition of Pro-ficiency in June 2024.

Services Highlights





TTM Revenue Decline

TTM Revenue Growth

TTM Revenue Growth

\$3.1M TTM Revenue⁽¹⁾


⁽¹⁾ The TTM revenue for the MC business unit only includes revenue since the acquisition of Pro-ficiency in June 2024.

Financial Results

Revenue - Q1



(in millions)




1Q25 Mix

Revenue - Trailing Twelve Months (TTM)




(in millions)



Software Solutions as % of Software Revenue






Software Performance Metrics - Q1



Commercial Customers




Software Performance Metrics - TTM



Commercial Customers


Avg. Revenue per Customer (in thousands)






Services Solutions as % of Services Revenue





Services Performance Metrics





14

Income Statement Summary (1)



(in millions, except Diluted EPS and Adjusted Diluted EPS)

	1Q25	% of Rev	1Q24 ⁽²⁾	% of Rev
Revenue	\$18.9	100%	\$14.5	100%
Cost of revenue	8.7	46%	4.7	32%
Gross profit	10.2	54%	9.0	62%
R&D	1.8	10%	1.2	8%
S&M	2.9	15%	2.0	14%
G&A	5.4	28%	4.9	34%
Total operating exp	10.1	53%	8.1	56%
Income from operations	0.1	1%	1.0	7%
Income before income taxes	0.3	1%	2.4	17%
Income taxes	(0.1)	-%	(0.5)	3%
Effective tax rate	24%		19%	
Net income	\$0.2	1%	\$1.9	13%
Diluted EPS	\$0.01		\$0.10	\leq
Adjusted EBITDA	\$4.5	24%	\$3.4	23%
Excluded items	\$3.2		\$1.8	
Adjusted Diluted EPS	\$0.17		\$0.18	

⁽¹⁾ Numbers may not add due to rounding

⁽²⁾ Reflects \$0.8 million reclassification from G&A expense to cost of revenue to provide more effective FY25 comparison.

Balance Sheet Summary



(in millions)

	November 30, 2024	August 31, 2024
Cash and short-term investments	\$18.2	\$20.3
Total current assets	40.4	39.3
Total assets	\$196.9	\$196.6
Current liabilities	9.7	12.1
Long-term liabilities	2.5	2.1
Total liabilities	12.2	14.2
Shareholders' equity	184.7	182.4
Total liabilities and shareholders' equity	\$196.9	\$196.6

Fiscal 2025 Guidance



	<u>Guidance</u>
Total Revenue	\$90M - \$93M
Total Revenue Growth	28% - 33%
Software Revenue Mix	55% - 60%
Adjusted EBITDA ⁽¹⁾ Margin	31% - 33%
Adjusted Diluted EPS ⁽²⁾	\$1.07 - \$1.20

⁽¹⁾ Adjusted EBITDA represents net income excluding the effect of interest expense (income), provision (benefit) for income taxes, amortization expense, intangible asset amortization, equity-based compensation expense, loss (gain) on currency exchange, goodwill impairment, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense and other items not indicative of our ongoing operating performance.

⁽²⁾ Adjusted net income and adjusted diluted earnings per share exclude the effect of amortization expense, equity-based compensation expense, loss (gain) on currency exchange, goodwill impairment, change in fair value of contingent consideration, reorganization expense, acquisition and integration expense and other items not indicative of our ongoing operating performance as well as the income tax provision adjustment for such charges.

Conclusion



CONTINUED LEADERSHIP POSITION IN LIFE SCIENCES TECHNOLOGY MARKET

Delivering on our commitment to scientific leadership	Developing organization to drive growth	Expanding our software and services portfolio	Creating shareholder value
Release of GastroPlusXRelease of Monolix R24	 Optimization of business unit structure following recent strategic 	 ALI: Pro-ficiency Performance Management software 	 Delivering consistent revenue growth and profitability
Release of ADMET Predictor Version 12	acquisitionsFormation of two new	platform • MC: Panorama KOL	 Strategic M&A
 Collaboration with USC to secure NIH Grant to 	business units following Pro-ficiency acquisition	Insights software platform	
develop new AI drug discovery offerings	 Focus on supporting accelerated growth in distributor network 		

WELL POSITIONED FOR FISCAL 2025 PERFORMANCE

Adjusted EBITDA Non-GAAP Reconciliation ⁽¹⁾



(in millions)

		FY24				FY24
	Q1	Q2	Q3	Q4	Q1	Full Year
Net Income	\$1.945	\$4.029	\$3.137	\$0.843	\$0.206	\$9.954
Excluding:						
Interest income and expense, net	(1.292)	(1.348)	(1.522)	(0.213)	(0.159)	(4.375)
Provision for income taxes	0.461	1.223	0.753	0.020	0.064	2.457
Depreciation and amortization	1.091	1.105	1.263	2.206	2.265	5.665
Stock-based compensation	1.303	1.585	1.665	1.387	1.589	5.940
(Gain) loss on currency exchange	(0.044)	0.098	(0.009)	(0.431)	0.015	(0.386)
Impairment of other intangibles		-	_	-	_	
Change in value of contingent consideration	(0.110)	0.440	(0.599)	(1.370)		(1.639)
Reorganization expense		_	<u> </u>	2	0.258	
Mergers & Acquisitions expense	0.034	0.003	0.898	1.706	0.255	2.641
Adjusted EBITDA	\$3.388	\$7.135	\$5.586	\$4.148	\$4.493	\$20.257

⁽¹⁾ Numbers may not add due to rounding

Adjusted Diluted EPS Non-GAAP Reconciliation ⁽¹⁾



(in millions, except Diluted EPS and Adjusted Diluted EPS)

		FY24			FY25	FY24
	Q1	Q2	Q3	Q4	Q1	Full Year
Net Income (GAAP)	\$1.945	\$4.029	\$3.137	\$0.843	\$0.206	\$9.954
Excluding:						
Amortization	0.991	0.991	1.122	2.059	2.130	5.163
Stock-based compensation	1.303	1.585	1.665	1.387	1.589	5.940
(Gain) loss on currency exchange	(0.044)	0.098	(0.009)	(0.431)	0.015	(0.386)
Mergers & Acquisitions expense	0.034	0.003	0.898	1.706	0.255	2.641
Change in value of contingent consideration	(0.110)	0.440	(0.599)	(1.370)	_	(1.639)
Reorganization expense	-	_	_	-	0.258	-
Tax effect on above adjustments	(0.417)	(0.746)	(0.603)	(0.554)	(1.007)	(2.320)
Adjusted Net income (Non-GAAP)	\$3.702	\$6.400	\$5.611	\$3.640	\$3.446	\$19.353
Weighted-avg. common shares outstanding:			1			5<
Diluted	20.279	20.315	20.433	20.338	20.266	20.301
Diluted EPS (GAAP)	\$0.10	\$0.20	\$0.15	\$0.04	\$0.01	\$0.49
Adjusted Diluted EPS (Non-GAAP)	\$0.18	\$0.32	\$0.27	\$0.18	\$0.17	\$0.95

⁽¹⁾ Numbers may not add due to rounding

S+ *SimulationsPlus*

Investor Relations Contact: Lisa Fortuna Financial Profiles 310-622-8251 slp@finprofiles.com